Nephros Q1 2025 Earnings Report

Nephros EPS Results

• Actual EPS: $0.05
• Consensus EPS: -$0.01
• Beat/Miss: Beat by +$0.06
• One Year Ago EPS: N/A

Nephros Revenue Results

• Actual Revenue: $4.88 million
• Expected Revenue: $3.67 million
• Beat/Miss: Beat by +$1.21 million
• YoY Revenue Growth: N/A

Nephros Announcement Details

• Quarter: Q1 2025
• Date: 5/15/2025
• Time: After Market Closes
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 4:00PM ET

Nephros (NASDAQ:NEPH), Inc. is a development-stage company specializing in advanced water filtration and purification technologies for medical, laboratory, industrial and defense applications. The company’s core offering centers on proprietary hollow fiber ultrafilters designed to remove bacteria, viruses, endotoxins and particulates from water streams. These ultrafilters are used in hemodialysis systems to protect patient treatment, in pharmaceutical and laboratory environments to ensure water quality and in critical field-deployable units for military and emergency response.

The company’s product portfolio includes standalone filtration cartridges for point-of-use and point-of-entry installations in dialysis clinics and hospitals, as well as bench-top and portable water purification systems. Nephros’ Water Purification System (WPS) is engineered to meet stringent U.S. Army and World Health Organization guidelines for field use, delivering potable water from untreated sources. In parallel, the MembraPure™ brand serves pharmaceutical and biotech customers requiring laboratory-grade water for research and manufacturing.

Nephros holds FDA 510(k) clearance for its medical-grade hollow fiber filters, underpinning its role in critical patient care applications. The company distributes products directly to healthcare providers and partners with OEMs and authorized distributors to serve markets across North America and select international territories. Its technology has been adopted by hospitals seeking to safeguard dialysis water and by research institutions requiring ultrapure water for sensitive assays.

Founded in 2005 and headquartered in Kinnelon, New Jersey, Nephros operates under the leadership of President and Chief Executive Officer Hal S. Zarem. The company maintains a focus on product innovation through ongoing research and development efforts, pursuing commercial partnerships and clinical collaborations to expand its footprint in water purification and filtration solutions.